An evaluation of the Fracture Risk Assessment Tool (FRAX®) as an indicator of treatment efficacy: the effects of bazedoxifene and raloxifene on vertebral, nonvertebral, and all clinical fractures as a function of baseline fracture risk assessed by FRAX®

[11] Binkley N(1999)Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial JAMA 282 637-532

[12] Cauley JA(2003)Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial Bone 33 522-1810

[13] Compston JE(2012)Effect of alendronate for reducing fracture by FRAX score and femoral neck bone mineral density: the Fracture Intervention Trial J Bone Miner Res 27 1804-1443

[14] wson-Hughes B(1995)Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis N Engl J Med 333 1437-2082

[15] El-Hajj FG(1998)Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial JAMA 280 2077-492

[16] Johansson H(1998)Prevention of bone loss with alendronate in postmenopausal women under 60 years of age N Engl J Med 338 485-261

[17] Leslie WD(2004)Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk J Clin Densitom 7 255-110

[18] Lewiecki EM(2005)Bone density and markers of bone turnover in predicting fracture risk and how changes in these measures predict fracture risk reduction Curr Osteoporos Rep 3 103-10

[19] Luckey M(2002)Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy J Bone Miner Res 17 1-289

[20] Oden A(2002)Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs Am J Med 112 281-3188

[11] Binkley N(1999)Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial JAMA 282 637-532

[12] Cauley JA(2003)Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial Bone 33 522-1810

[13] Compston JE(2012)Effect of alendronate for reducing fracture by FRAX score and femoral neck bone mineral density: the Fracture Intervention Trial J Bone Miner Res 27 1804-1443

[14] wson-Hughes B(1995)Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis N Engl J Med 333 1437-2082

[15] El-Hajj FG(1998)Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial JAMA 280 2077-492

[16] Johansson H(1998)Prevention of bone loss with alendronate in postmenopausal women under 60 years of age N Engl J Med 338 485-261

[17] Leslie WD(2004)Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk J Clin Densitom 7 255-110

[18] Lewiecki EM(2005)Bone density and markers of bone turnover in predicting fracture risk and how changes in these measures predict fracture risk reduction Curr Osteoporos Rep 3 103-10

[19] Luckey M(2002)Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy J Bone Miner Res 17 1-289

[20] Oden A(2002)Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs Am J Med 112 281-3188